The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinoma
Cell Biochemistry and Function · 2023-10 · 41 (7) · 788-800
DOI: 10.1002/cbf.3828 ↗Kurz gefasst
Zurückgezogene Publikation in der Zeitschrift Cell Biochemistry and Function, online erschienen am 20.07.2023. Verfasst von Nabil M Abdel-Hamid und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit nennt 44 Literaturangaben.
Abstract (Originalsprache)
Currently, many challenges are associated with hepatocellular carcinoma (HCC) as the failure of early diagnosis, and the lack of effective therapy. This study aimed to investigate the possible role of tuftelin 1 (TUFT 1) in the early diagnosis of HCC and evaluate the potential contribution of the TUFT 1/Ca +2 /phosphinositol 3 kinase (PI3K) pathway in dantrolene sodium (Dan) therapeutic outcomes. The study was performed on two sets of rats, the staging (30 rats) and treatment sets (80 rats). HCC was induced by a single dose of diethylnitrosamine (DENA). The hepatic content of TUFT 1 protein was assayed via western blot and immunohistochemistry (IHC), while PI3K, vascular endothelial growth factor (VEGF), Cyclin D1, and matrix‐metalloproteinase‐9 (MMP‐9) contents were assessed using enzyme‐linked immunosorbent assay. Hepatic and serum calcium were measured colorimetrically. Furthermore, the nuclear proliferation marker, (Ki‐67), (Kiel [Ki] where the antibody was produced in the University Department of Pathology and the original clone number is 67)—expression was assessed by IHC. TUFT 1/Ca +2 /PI3K signaling pathway was progressively activated in the 3 studied stages of HCC with subsequent upregulation of angiogenesis, cell cycle, and metastasis. More interestingly, Dan led to TUFT 1/Ca +2 /PI3K pathway disruption by diminution of the hepatic contents of TUFT 1, calcium, PI3K, VEGF, Cyclin D1, and MMP‐9 in a dose‐dependent pattern. TUFT 1 can serve as a theranostic biomarker in HCC. Moreover, Dan exerted an antineoplastic effect against HCC via the interruption of TUFT 1/Ca +2 /PI3K pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biochemistry, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Department of Pharmacology and Toxicology, Faculty of Pharmacy, Kafrelsheikh University, Kafrelsheikh, Egypt.
- Department of Chemistry (Biochemistry Division), Faculty of Science, Mansoura University, Mansoura, Egypt.
- Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Zitieren
APA
Abdel-Hamid, N. M., Zakaria, S. M., Ansary, A. M., El-Senduny, F. F., & El-Shishtawy, M. M. (2023). The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinoma. Cell Biochemistry and Function, 41(7), 788-800. https://doi.org/10.1002/cbf.3828
Vancouver
Abdel-Hamid NM, Zakaria SM, Ansary AM, El-Senduny FF, El-Shishtawy MM. The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinoma. Cell Biochemistry and Function. 2023;41(7):788-800. doi:10.1002/cbf.3828
BibTeX
@article{AbdelHamid2023,
author = {Abdel-Hamid, Nabil M and Zakaria, Sherin M and Ansary, Abeer M and El-Senduny, Fardous F and El-Shishtawy, Mamdouh M},
title = {The expression of tuftelin 1 as a new theranostic marker in early diagnosis and as a therapeutic target in hepatocellular carcinoma},
journal = {Cell Biochemistry and Function},
year = {2023},
volume = {41},
number = {7},
pages = {788--800},
doi = {10.1002/cbf.3828}
}
EUVIMED